All In Biotech

Drug Trial Radar · NCT02629874

PK/PD of EA-230 During Endotoxemia

Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia

Last checked: Nov 19, 2026Latest source record: Jun 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Feb 2015

Primary completion

Jul 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Exponential Biotherapies Inc.
First posted
Dec 14, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

EA-230 is a newly developed synthetic compound with anti-inflammatory properties. Pre-clinical data indicate that EA-230 may be a valuable treatment for systemic inflammation resulting from a variety of causes such as surgery, trauma, infection, irradiation and others. Although previous studies in healthy volunteers have shown an excellent safety profile, the safety and tolerability of higher doses administered per continuous infusion need to be investigated. Also, the dose-effect relation on systemic inflammation needs to be further elucidated before a phase II trial in patients can be commenced.

Conditions

  • Endotoxemia
  • Systemic Inflammatory Response

Interventions

  • EA-230Drug

    at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.

  • EndotoxinDrug

    at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability expressed in treatment related (serious) adverse eventsTime frame: total (S)AE's at day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Intensive care, research unit, Radboud University Medical Centre

    Nijmegen, Gelderland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.